New York State Common Retirement Fund Purchases 972 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

New York State Common Retirement Fund raised its holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 0.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 168,367 shares of the medical instruments supplier’s stock after purchasing an additional 972 shares during the quarter. New York State Common Retirement Fund owned 0.29% of Merit Medical Systems worth $16,284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Creative Planning boosted its position in shares of Merit Medical Systems by 26.9% in the third quarter. Creative Planning now owns 19,053 shares of the medical instruments supplier’s stock valued at $1,883,000 after acquiring an additional 4,033 shares during the period. International Assets Investment Management LLC bought a new stake in shares of Merit Medical Systems in the 3rd quarter worth approximately $21,156,000. Assenagon Asset Management S.A. bought a new stake in Merit Medical Systems in the third quarter valued at $9,182,000. Dakota Wealth Management raised its stake in Merit Medical Systems by 42.9% in the third quarter. Dakota Wealth Management now owns 4,486 shares of the medical instruments supplier’s stock worth $443,000 after buying an additional 1,347 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC purchased a new stake in Merit Medical Systems in the third quarter worth $309,000. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on MMSI. Robert W. Baird upped their target price on shares of Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. StockNews.com downgraded Merit Medical Systems from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Wells Fargo & Company raised shares of Merit Medical Systems from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $103.00 to $120.00 in a report on Wednesday, December 11th. Raymond James upped their target price on shares of Merit Medical Systems from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Tuesday, December 31st. Finally, Piper Sandler reiterated an “overweight” rating and set a $116.00 price target (up previously from $114.00) on shares of Merit Medical Systems in a research note on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Merit Medical Systems currently has an average rating of “Moderate Buy” and an average price target of $109.80.

Merit Medical Systems Trading Down 2.4 %

Shares of Merit Medical Systems stock opened at $103.16 on Monday. Merit Medical Systems, Inc. has a fifty-two week low of $70.70 and a fifty-two week high of $111.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. The company has a market capitalization of $6.01 billion, a P/E ratio of 50.57, a P/E/G ratio of 2.34 and a beta of 0.87. The company has a fifty day moving average of $102.64 and a 200 day moving average of $99.64.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.